Arvind Utchanah
Director of Finance/CFO en KNIGHT THERAPEUTICS INC. .
Fortuna: 153 413 $ al 31/03/2024
Perfil
Arvind Utchanah is currently the Chief Financial Officer at Knight Therapeutics, Inc. He previously worked as the Director-Finance, Accounting & Financial Planning at Paladin Labs, Inc. from 2012 to 2016.
Mr. Utchanah has an undergraduate degree from McGill University and a graduate degree from Concordia University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 12/04/2024 | 39 136 ( 0.04% ) | 153 413 $ | 31/03/2024 |
Cargos activos de Arvind Utchanah
| Empresas | Cargo | Inicio |
|---|---|---|
| KNIGHT THERAPEUTICS INC. | Director of Finance/CFO | 30/03/2020 |
Antiguos cargos conocidos de Arvind Utchanah.
| Empresas | Cargo | Fin |
|---|---|---|
| PALADIN LABS INC. | Director of Finance/CFO | 01/06/2016 |
Formación de Arvind Utchanah.
| McGill University | Undergraduate Degree |
| Concordia University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| KNIGHT THERAPEUTICS INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Paladin Labs, Inc.
 Paladin Labs, Inc. Pharmaceuticals: MajorHealth Technology Paladin Labs Inc. operates as pharmaceutical company. It engages in developing, acquiring, in-licensing, marketing, and distributing innovative pharmaceutical products in Canada and internationally. The firm's products include Abstral, GlucaGen, Metadol, Plan B, Pennsaid, Seasonale, Testim, Twinject, Dexedrin, Tridural, and Trelstar. The company was founded by Jonathan Ross Goodman and Mark Beaudet on February 25, 1983 and is headquartered in Montreal, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Arvind Utchanah
